Wechselwirkungen · Xagrid
Xagrid 0.5 mg hard capsules. · Abschnitt 4.5 · PDF-Seite 5
HOS-111701 · Präparat HOS-093587
Effects of other active substances on anagrelide In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide. CYP1A2 inhibitors Anagrelide is primarily metabolised by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine and enoxacin, and such medicinal products could theoretically adversely influence the clearance of anagrelide. CYP1A2 inducers CYP1A2 inducers (such as omeprazole) could decrease the exposure of anagrelide (see section 5.2). The consequences on the safety and efficacy profile of anagrelide are not established. Therefore, clinical and biological monitoring is recommended in patients taking concomitant CYP1A2 inducers. If needed, anagrelide dose adjustment could be made.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enoxacin (HOS-111703) digoxin (HOS-086172) fluvoxamine (HOS-085908) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-20T12:00:00Z · SHA-256 87cdc695145c0255ddafd5a98b35d5237ee320bd26290f38f993752bd4763fab · Passage 603082c28f5d37d2448c54c7032cdcbcb40f39ceaa85e4abc664fafbae886638 · Zeichen 161–1024 im Abschnitt